PET imaging with 18F-FLT and thymidine analogs: Promise and pitfalls

Journal of Nuclear Medicine

Volumn 44, Issue 9, 2003, Pages 1432-1434

  Shields, Anthony F ^a,b  

^a HARPER UNIVERSITY HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE; ANTIVIRUS AGENT; DNA; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; PYRIMIDINE DERIVATIVE; THYMIDINE DERIVATIVE; TRACER; ZIDOVUDINE; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; DIAGNOSTIC AGENT; FLUORINE; RADIOPHARMACEUTICAL AGENT; THYMIDINE;

CANCER STAGING; CANCER THERAPY; CELL ACTIVITY; CLINICAL PRACTICE; DNA SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS; IMAGING; NOTE; ONCOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR CLASSIFICATION; TUMOR DIAGNOSIS; TUMOR GROWTH; ANIMAL; HUMAN; METABOLISM; METHODOLOGY; NEOPLASM; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY;

ANIMALS; DIDEOXYNUCLEOSIDES; FLUORINE RADIOISOTOPES; HUMANS; NEOPLASM STAGING; NEOPLASMS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; THYMIDINE;

EID: 0142212381     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (16)

1. 18F-FDG J Nucl Med. 2003;44:1426-1431
2. 11C]thynudine for quantification of cellular proliferation with PET. Int J Rad Appl Instrum [A]. 1991;42:103-104.
3. 11C labeled thymidine for tumor visualization using positron emission tomography Int J Applied Radiat Isot 1984;35:705-708.
4. 124I]iododeoxyuridine. Cancer Res 2000;60:624-635.
5. 76Br] Bromodeoxyuridme PET in tumor-bearing animals. Nucl Med Biol. 2001;28:51-57.
6. Flexner C, van der Horst C, Jacobson MA, et al. Relationship between plasma concentrations of 3′-deoxy-3′-fluorothymidine (alovudine) and antiretroviral activity in two concentration-controlled trials J Infect Dis 1994;170:1394-1403.
7. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334-1336.
8. Vesselle H, Grierson J, Muzi M, et al. In vivo validation of 3′deoxy-3′-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res. 2002;8:3315-3323.
9. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwanz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med. 2002;43:1210-1217.
10. Shields A, Grierson JR, Muzik O, et al. Kinetics of 3′-deoxy- 3′-[F-18]fluorothymidine uptake and retention in dogs. Mol Imaging Biol. 2002;4:83-89.
11. 3H]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines. Nucl Med Biol 2002;29:281-287.
12. Wells P, Gunn RN, Alison M, et al. Assessment of proliferation in vivo using 2-[(11)C]thymidine positron emission tomography in advanced intraabdominal malignancies. Cancer Res. 2002;62:5698-5702.
13. Bergstrom M, Lu L, Fasth KJ, et al. In vitro and animal validation of bromme-76-bromodeoxyuridine as a proliferation marker. J Nucl Med. 1998; 39:1273-1279
14. 11C]-FMAU): a potential nucleoside analog for in vivo study of cellular proliferation with PET. Nucl Med Biol 1995;22:783-789.
15. Mangner TJ, Klecker RW, Andersen L, Shields AF Synthesis of 2′-deoxy-2′-[(18)F]fluoro-beta-D-arabinofuranosyl nucleosides, [(18)F]FAU, [(18)F]FMAU, [(18)F]FBAU and [(18)F]FIAU, as potential PET agents for imaging cellular proliferation. Nucl Med Biol 2003;30:215-224.
16. 76Br-BFU as proliferation markers J Nucl Med. 2002;43:1688-1698.